Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib and Pemetrexed in EGFR-mutated NSCLC with Leptomeningeal Metastasis
NCT06315686Phase 2Recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), leptomeningeal metastasis (LM), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Started Sep 2022; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06315686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315686.